Endocrine Abstracts

Introduction: Temozolomide (TMZ) treatment has been used for aggressive pituitary tumours with positive results, but has proven ineffective in controlling tumour regrowth in cases of disease recurrence. TMZ resistance has been linked to the expression of O6-methyl-guanine-DNA-methyltransferase (MGMT) protein and mismatch repair components (MMR). In the present study, we describe the development of an in vitro model of acquired resistance to TMZ and the mechanisms invo...